Cadrenal Therapeutics Files 8-K on Security Holder Votes
Ticker: CVKD · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1937993
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: CADX
TL;DR
CADX filed an 8-K for shareholder votes - details TBD.
AI Summary
Cadrenal Therapeutics, Inc. filed an 8-K on September 24, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions presented to the security holders.
Why It Matters
This filing indicates that Cadrenal Therapeutics held a meeting or took action requiring a vote from its shareholders, which could pertain to corporate governance or strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- September 24, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Cadrenal Therapeutics' security holders?
The filing states that matters were submitted to a vote of security holders, but does not specify what those matters were.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 24, 2025.
What is Cadrenal Therapeutics, Inc.'s principal executive office address?
Cadrenal Therapeutics, Inc.'s principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
What is the SEC file number for Cadrenal Therapeutics, Inc.?
The SEC file number for Cadrenal Therapeutics, Inc. is 001-41596.
What is the SIC code for Cadrenal Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Cadrenal Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-24 16:05:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
Filing Documents
- ea0258629-8k_cadrenal.htm (8-K) — 31KB
- 0001213900-25-091109.txt ( ) — 194KB
- cvkd-20250924.xsd (EX-101.SCH) — 3KB
- cvkd-20250924_lab.xml (EX-101.LAB) — 33KB
- cvkd-20250924_pre.xml (EX-101.PRE) — 22KB
- ea0258629-8k_cadrenal_htm.xml (XML) — 4KB
07. Submission
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 24, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2025 annual meeting of stockholders (the "2025 Annual Meeting") at which the Company's stockholders voted on the following two (2) proposals and cast their votes as described below. These matters are described in detail in the definitive proxy statement on Schedule 14A for the 2025 Annual Meeting filed with the Securities and Exchage Commission on July 31, 2025 (the "Proxy Statement"). As of July 28, 2025, the record date of the 2025 Annual Meeting, there were 2,046,854 shares of Common Stock issued and outstanding and entitled to vote at the 2025 Annual Meeting. Present in person or by proxy at the 2025 Annual Meeting were 1,284,746 shares of Common Stock, which constituted a quorum. The final voting results for each item of business voted upon at the 2025 Annual Meeting, as described in the Proxy Statement, is set forth below. Proposal 1 . Election of Directors Proposal . The following individual was elected as a Class III director, to serve until the Company's 2028 annual meeting of stockholders and until his successor has been duly elected and qualified with the following votes: Name of Director Votes For Withheld Broker Non-Votes Steven Zelenkofske 669,494 15,099 600,153 Proposal 2 . Auditor Ratification Proposal . The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 1,207,152 64,913 12,681 0 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 24, 2025 CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chairman and Chief Executive Officer 2